966P Evaluation of the prognostic marker of PD-L1 expression after combined radio-chemotherapy in patients with non-small cell lung cancer (NSCLC) stage III

Abstract

The PACIFIC study showed that pts with locally advanced, unresectable NSCLC after radio-chemotherapy derived a benefit in PFS and OS when treated with durvalumab. In a post hoc analysis this effect was limited to pts with a PD-L1 of >1%. In contrast, in pts with PD-L1 of <1%, no benefit was seen partly due to the fact that the outcome in the control arm was surprisingly favorable. Thus, it could be speculated that lack of PD-L1 expression confers a favorable outcome after radio-chemotherapy in stage III NSCLC.